Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.

Wolff JM, Boeckmann W, Borchers H, Handt S, Reineke T, Jakse G.

Urol Int. 1996;57(3):170-4.

PMID:
8912446
3.

Evaluation of patients with diseases of the prostate using prostate-specific antigen density.

Wolff JM, Boeckmann W, Effert PJ, Handt S, Jakse G.

Br J Urol. 1995 Jul;76(1):41-6.

PMID:
7544203
4.

Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.

Wolff JM, Borchers H, Brehmer B Jr, Brauers A, Jakse G.

Urol Int. 1998;60(3):152-5.

PMID:
9644784
5.

Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.

Udeh EI, Nnabugwu II, Ozoemena FO, Ugwumba FO, Aderibigbe AS, Ohayi SR, Echetabu KN.

World J Surg Oncol. 2016 Jun 29;14(1):174. doi: 10.1186/s12957-016-0921-6.

6.
7.

Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.

Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.

Anticancer Res. 2000 Nov-Dec;20(6D):4995-6.

PMID:
11326656
8.

Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.

Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT.

Urology. 2009 Jul;74(1):177-83. doi: 10.1016/j.urology.2008.10.062. Epub 2009 May 9.

PMID:
19428074
9.

Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.

Marley GM, Miller MC, Kattan MW, Zhao G, Patton KP, Vessella RL, Wright GL Jr, Schellhammer PF, Veltri RW.

Urology. 1996 Dec;48(6A Suppl):16-22.

PMID:
8973695
10.

Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.

Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G.

Anticancer Res. 1997 Jul-Aug;17(4B):2993-4.

PMID:
9329583
12.

Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.

Wolff JM, Scholz A, Boeckmann W, Jakse G.

Eur Urol. 1994;25(4):295-8; discussion 304.

PMID:
7519991
13.

Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia.

Wolff JM, Borchers H, Effert PJ, Habib FK, Jakse G.

Br J Urol. 1996 Sep;78(3):409-13.

PMID:
8881952
14.

Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.

Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S.

Cancer Biomark. 2015;15(3):317-23. doi: 10.3233/CBM-150458.

PMID:
25586096
15.

[Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].

Chen ZD, Wei SM, Cai SL.

Zhonghua Wai Ke Za Zhi. 2004 May 22;42(10):593-5. Chinese.

PMID:
15265401
16.

Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.

Meigs JB, Barry MJ, Oesterling JE, Jacobsen SJ.

J Gen Intern Med. 1996 Sep;11(9):505-12.

PMID:
8905498
17.

Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.

Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH Jr.

Urology. 1996 Dec;48(6A Suppl):23-32.

PMID:
8973696
18.

Urinary prostate specific antigen: is the clinical use likely?

Pejcic T, Hadzi-Djokic J, Acimovic M, Topuzovic C, Milkovic B, Janjic A.

Acta Chir Iugosl. 2005;52(4):69-74.

PMID:
16673599
19.
20.

Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer.

Matsuyama H, Baba Y, Yamakawa G, Yamamoto N, Naito K.

Int J Urol. 2000 Nov;7(11):409-14.

Supplemental Content

Support Center